A barrier moisturiser added to minocycline eased redness in erythematotelangiectatic rosacea

Design

Randomised controlled trial, 28 days

Population

75 patients with erythematotelangiectatic rosacea, all on oral minocycline 50 mg daily

Primary outcome

Erythema measures and skin barrier indices (redness, hydration, transepidermal water loss) and quality of life

Effect

Greater improvement in redness, hydration and RosQol with the study moisturiser; effect sizes not reported in the abstract

In this 28-day randomised trial of 75 Chinese patients with erythematotelangiectatic rosacea, everyone took oral minocycline 50 mg daily and used a moisturiser twice daily. The experimental group, 39 patients, received a moisturiser containing Centella asiatica extract, ceramide NP and panthenol, while 36 controls used a comparator product.

The authors report that changes from baseline to day 28 in measured redness, facial red area, stratum corneum hydration and the rosacea quality-of-life score were greater with the study moisturiser, and the clinician erythema rank was higher in the control group. Adverse events were mild and self-limiting. The abstract does not give effect sizes, so the size of the benefit cannot be judged.

The design does not isolate the moisturiser from background minocycline, follow-up was short, and the product is the study's own formulation. Supporting skin barrier care in rosacea is common practice, and this finding fits with it without establishing that a specific product is better.

• Barrier repair alongside systemic treatment is reasonable in rosacea.
• The trial lasted 28 days and was in Chinese patients, so long-term and wider benefit are unknown.
• No effect sizes were reported in the abstract; judge cautiously.
• Choose fragrance-free products and check for irritation in sensitive skin.
• Do not read the trial as evidence for this particular product over others.

Why it matters

It supports a low-risk step in rosacea care that is often an afterthought.

Don't overread it

The trial tested an adjunct product on top of minocycline over four weeks and does not show the moisturiser works alone.

The statistics, in plain English

Because the abstract reports significance but not the size of changes, we cannot say whether the differences were big enough to matter to patients. A short trial cannot show whether benefits last once treatment stops.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.